Search results
Showing 46 to 60 of 369 results for depression
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Preventing excess winter deaths and illness associated with cold homes (QS117)
This quality standard covers reducing the health risks (including preventable deaths) associated with cold homes. It includes identifying people at risk who are particularly vulnerable to the cold, such as young children, older people, and people with cardiovascular disease or mental health problems. It describes high-quality care in priority areas for improvement.
View quality statements for QS117Show all sections
Sections for QS117
- Quality statements
- Quality statement 1: Year-round planning to identify vulnerable local populations
- Quality statement 2: Identifying people vulnerable to health problems associated with a cold home
- Quality statement 3: Single-point-of-contact health and housing referral service
- Quality statement 4: Asking people about keeping warm at home
- Quality statement 5: Identifying people vulnerable to health problems associated with cold homes on admission
- Quality statement 6: Discharge plan
- About this quality standard
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Recommendation ID NG54/3 Question Psychological interventions for depression and anxiety disorders in adults with mild to moderate...
This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.
View quality statements for QS23Show all sections
Sections for QS23
- Quality statements
- Quality statement 1: Needle and syringe programmes
- Quality statement 2: Assessment
- Quality statement 3: Families and carers
- Quality statement 4: Blood-borne viruses
- Quality statement 5: Information and advice
- Quality statement 6: Keyworking – psychosocial interventions
- Quality statement 7: Recovery and reintegration
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.
Gambling-related harms: identification, assessment and management (NG248)
This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.
Diabetes: annual psychological assessment (children T2DM) (IND314)
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: annual psychological assessment (children T1DM) (IND313)
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
moderate to severe depression? Any explanatory notes(if applicable) Making choices about treatments As for mild depression,...
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
Borderline personality disorder: recognition and management (CG78)
This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.
Early years: promoting health and wellbeing in under 5s (QS128)
This quality standard covers services to support the health, and social and emotional wellbeing of children under 5, including vulnerable children who may need extra support. It includes health visitor services, childcare and early years education, and early intervention services in children’s social care. It describes high-quality care in priority areas for improvement.